GlassScriptPhysician profile
Amanda M Wu
NPI 1497754014
$8,599.23
in general payments reported to CMS, 2019-2025
27 companies · $827 in 2025
The $827 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,628 · 2020: $1,098 · 2021: $1,298 · 2022: $1,381 · 2023: $1,107 · 2024: $1,260 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,251.77 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,182.52 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $908.29 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $715.59 | 2024-2025 | |
| Novo Nordisk INC | $688.42 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.65 | 2019-2025 | Jardiance |
| Allergan, INC. | $483.29 | 2019-2020 | |
| Amgen INC. | $415.57 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $355.40 | 2021-2024 | Ubrelvy, Vraylar |
| Novartis Pharmaceuticals Corporation | $271.69 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $156.58 | 2022-2023 | Quviviq |
| Depuy Synthes Sales INC. | $119.93 | 2019 | |
| Merck Sharp & Dohme LLC | $113.42 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $72.59 | 2019 | |
| Pfizer INC. | $67.71 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $48.48 | 2021-2023 | Seglentis |
| Sanofi-Aventis U.S. LLC | $38.02 | 2021-2023 | |
| Topcon Healthcare Solutions, INC. | $33.86 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $33.65 | 2021 | |
| Phadia US INC. | $31.91 | 2019-2025 | Immunocap |
| Avvisto Therapeutics, LLC | $20.12 | 2025 | Cycloset |
| Gilead Sciences, INC. | $19.58 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.95 | 2019 | |
| Protega Pharmaceutials INC | $17.36 | 2022 | |
| Boston Scientific Corporation | $16.03 | 2019 | |
| Horizon Therapeutics Plc | $12.67 | 2019 | |
| Seqirus USA INC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.